LuciPazo is a targeted antineoplastic agent belonging to the multi-kinase inhibitor class, indicated for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. The active pharmaceutical ingredient is pazopanib at a strength of 200 mg supplied as film-coated oral tablets (Pazopanib Tablets 200 mg). The product is developed and manufactured by Lucius Pharmaceuticals.
Pazopanib is a potent oral selective inhibitor of receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-alpha and beta), and stem cell factor receptor (c-Kit). Blockade of these kinases suppresses angiogenesis (the formation of new blood vessels supplying the tumor), reduces tumor blood supply, and inhibits tumor cell proliferation.
Supplied in a package containing 120 tablets of 200 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.
Key Clinical Features and Advantages of LuciPazo 200 mg:
- ✅ Multi-Targeted Anti-Angiogenic Action: Blockade of VEGFR, PDGFR, and c-Kit to deprive tumors of blood supply.
- ✅ Proven Efficacy: High therapeutic effectiveness in renal cell carcinoma and soft tissue sarcomas.
- ✅ Convenient Oral Dosing: Taken orally once daily on an empty stomach.
- ✅ Optimal Strength: 200 mg tablets allow flexible dose titration and adjustment.
- ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Votrient).